Karacin, C. Et Al. 2024. Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer. Future oncology (London, England) , vol.20, no.4 , 207-214.

Karacin, C., Sunar, V., Urakci, Z., YILMAZ, A., Ayhan, M., Ersoy, M., ... Guven, D. C.(2024). Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer. Future oncology (London, England) , vol.20, no.4, 207-214.

Karacin, Cengiz Et Al. "Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer," Future oncology (London, England) , vol.20, no.4, 207-214, 2024

Karacin, Cengiz Et Al. "Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer." Future oncology (London, England) , vol.20, no.4, pp.207-214, 2024

Karacin, C. Et Al. (2024) . "Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer." Future oncology (London, England) , vol.20, no.4, pp.207-214.

@article{article, author={Cengiz Karacin Et Al. }, title={Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer}, journal={Future oncology (London, England)}, year=2024, pages={207-214} }